COMMUNIQUÉS West-GlobeNewswire

-
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
17/10/2024 -
AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA
17/10/2024 -
Enlitic Acquires Laitek, Revolutionizing Medical Imaging Data Management
17/10/2024 -
OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index
17/10/2024 -
OSE Immunotherapeutics présente une nouvelle technologie bispécifique de « Cis-Démasquage » pour la conception de médicaments à base de cytokines avec un indice thérapeutique amélioré
17/10/2024 -
EssilorLuxottica: Q3/9M 2024 Revenue - Revenue keeping a solid 4% growth
17/10/2024 -
EssilorLuxottica: Chiffre d’affaires T3/9M 2024 - Solide croissance du chiffre d'affaires à +4 %
17/10/2024 -
Virbac: Strong revenue growth as of the end of September at +12.6% and +8.6% at constant exchange rates and scope. 2024 targets maintained.
17/10/2024 -
VIRBAC: Croissance soutenue du chiffre d’affaires à fin septembre de +12,6% et +8,6% à taux de change et périmètre constants. Maintien des objectifs pour 2024.
17/10/2024 -
Emergex Announces Company Name Change to “Gylden Pharma Limited” Reflecting Company’s Commitment to Advanced Core Technologies and Expanded Product Pipeline
17/10/2024 -
Dr. Wenming Chen to Receive Asian Myeloma Network Distinguished Service Award at the 8th AMN Summit in Seoul
17/10/2024 -
Rapafusyn Pharmaceuticals to Present In Vivo Data on ENT1 Inhibitor for Acute Kidney Injury at the American Society for Nephrology (ASN Kidney Week 2024)
17/10/2024 -
New Study Reveals Promising Outcomes for Minimally Invasive Sacrospinous Ligament Fixation Using EnPlace® for Treating Pelvic Organ Prolapse in Older Women
17/10/2024 -
WellRithms Selected for BenefitsPRO’s 2024 Luminaries Awards
17/10/2024 -
Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy
17/10/2024 -
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow
17/10/2024 -
TOMI Environmental Solutions, Inc. Announces Record Q3 2024 iHP Corporate Service Revenue
17/10/2024 -
RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing
17/10/2024 -
Nordic Naturals Completes 40th Annual California Coastal Cleanup with National Retail Support
17/10/2024
Pages